MA38380A1 - Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) - Google Patents

Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)

Info

Publication number
MA38380A1
MA38380A1 MA38380A MA38380A MA38380A1 MA 38380 A1 MA38380 A1 MA 38380A1 MA 38380 A MA38380 A MA 38380A MA 38380 A MA38380 A MA 38380A MA 38380 A1 MA38380 A1 MA 38380A1
Authority
MA
Morocco
Prior art keywords
egfr
activation
mutant forms
epidermal growth
growth receptor
Prior art date
Application number
MA38380A
Other languages
English (en)
Inventor
David Yunzhi Li
Jiabing Wang
Zhenfan Yang
Qingbei Zeng
Xiaolin Zhang
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of MA38380A1 publication Critical patent/MA38380A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne des composés de formule (i), ou un sel pharmaceutiquement acceptable de ceux-ci : formule (i) qui possèdent une activité inhibitrice contre l'activation des formes mutantes de l'egfr, et qui sont par conséquent utiles pour leur activité anticancéreuse et dans les méthodes destinées à traiter le corps humain ou animal. L'invention concerne également des compositions pharmaceutiques les contenant et leur utilisation dans la fabrication de médicaments servant à produire un effet anticancéreux chez un animal à sang chaud tel que l'homme.
MA38380A 2013-03-06 2015-09-04 Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) MA38380A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013072250 2013-03-06
PCT/GB2014/050655 WO2014135876A1 (fr) 2013-03-06 2014-03-05 Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)

Publications (1)

Publication Number Publication Date
MA38380A1 true MA38380A1 (fr) 2017-01-31

Family

ID=50288181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38380A MA38380A1 (fr) 2013-03-06 2015-09-04 Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)

Country Status (42)

Country Link
US (4) US9066979B2 (fr)
EP (2) EP3342770B1 (fr)
JP (1) JP5894714B1 (fr)
KR (1) KR101645112B1 (fr)
CN (1) CN105209456B (fr)
AP (1) AP2015008696A0 (fr)
AR (1) AR095039A1 (fr)
AU (1) AU2014224382B2 (fr)
BR (1) BR112015020787B1 (fr)
CA (1) CA2901269C (fr)
CL (1) CL2015002361A1 (fr)
CR (1) CR20150450A (fr)
CY (1) CY1119487T1 (fr)
DK (1) DK2964638T3 (fr)
DO (1) DOP2015000189A (fr)
ES (1) ES2642201T3 (fr)
GT (1) GT201500251A (fr)
HR (1) HRP20171689T1 (fr)
HU (1) HUE034568T2 (fr)
IL (1) IL240578B (fr)
LT (1) LT2964638T (fr)
MA (1) MA38380A1 (fr)
ME (1) ME03041B (fr)
MX (1) MX362247B (fr)
MY (1) MY186126A (fr)
NI (1) NI201500123A (fr)
NO (1) NO2964638T3 (fr)
PE (1) PE20152000A1 (fr)
PH (1) PH12015501965B1 (fr)
PL (1) PL2964638T3 (fr)
PT (1) PT2964638T (fr)
RS (1) RS56566B1 (fr)
RU (1) RU2656597C2 (fr)
SG (1) SG11201506487YA (fr)
SI (1) SI2964638T1 (fr)
SM (1) SMT201700542T1 (fr)
TN (1) TN2015000368A1 (fr)
TW (1) TWI543977B (fr)
UA (1) UA115686C2 (fr)
UY (1) UY35369A (fr)
WO (1) WO2014135876A1 (fr)
ZA (1) ZA201507353B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362247B (es) * 2013-03-06 2019-01-09 Astrazeneca Ab Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico.
DK3035936T3 (da) 2013-08-23 2019-06-11 Neupharma Inc Visse kemiske enheder, sammensætninger og fremgangsmåder
EP3201190A4 (fr) 2014-10-01 2018-03-14 Sun Pharmaceutical Industries Ltd Forme cristalline de dimaléate d'afatinib
EP3270694A4 (fr) 2015-02-17 2018-09-05 Neupharma, Inc. Entités chimiques, compositions et méthodes particulières
CN105859641B (zh) 2015-05-05 2018-11-16 杭州华东医药集团新药研究院有限公司 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
CN105503906B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物a晶型及其制备方法
CN105503905B (zh) * 2015-12-09 2018-09-11 上海宣创生物科技有限公司 一种三唑并吡嗪衍生物b晶型及其制备方法
EP3497087B1 (fr) 2016-08-15 2021-11-10 Neupharma, Inc. Dérivés de pyrrolo[1,2-c]pyrimidine, imidazol[1,5-c]pyrimidine, quinazoline, purine et imidazo[1,5-a][1,3,5]triazine en tant qu'inhibiteurs de la tyrosine kinase pour le traitement du cancer
CN108658946B (zh) * 2017-03-28 2020-06-16 焦玉奇 新颖的喹唑啉抑制剂
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN109721551B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种3,4-二氢-7-甲氧基-4-氧代喹唑啉-6-醇乙酸酯的制备方法
CN109721552B (zh) * 2017-10-30 2022-09-20 上海北卡医药技术有限公司 一种吉非替尼的制备方法
JP7550646B2 (ja) 2018-02-08 2024-09-13 ニューファーマ，インク． 特定の化学物質、組成物、および方法
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法
BR112021004527A2 (pt) 2018-09-14 2021-06-08 Spectrum Pharmaceuticals, Inc. kits e métodos para tratamento contra câncer
CN110903283B (zh) * 2018-09-17 2021-01-01 南京雷正医药科技有限公司 一种取代的喹唑啉类化合物、包含该化合物的药物组合物和该化合物的用途
WO2020057403A1 (fr) * 2018-09-18 2020-03-26 北京越之康泰生物医药科技有限公司 Dérivé d'indole et son application médicale
KR102668124B1 (ko) 2019-02-02 2024-05-23 노바온코 제이에스 테라퓨틱스 컴퍼니 리미티드 Pd-l1 면역조절제인 비닐 피리딘 카르복사미드 화합물
AU2020214518B2 (en) 2019-02-02 2022-12-15 Novaonco Js Therapeutics Co., Ltd. Fluorovinylbenzamide compound as PD-L1 immunomodulator
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
EA202192552A1 (ru) 2019-03-29 2021-12-17 Астразенека Аб Осимертиниб для применения в лечении немелкоклеточного рака легкого
WO2020254565A1 (fr) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Inhibiteurs d'egfr pour le traitement du cancer
CN110590683B (zh) * 2019-10-11 2022-08-19 山东四环药业股份有限公司 一种靶向药物azd3759中间体的制备方法
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4093394A1 (fr) 2020-01-20 2022-11-30 Astrazeneca AB Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour le traitement du cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN111675700A (zh) * 2020-06-22 2020-09-18 通化师范学院 一种抗癌新药azd3759的制备方法
CN111662273A (zh) * 2020-06-22 2020-09-15 通化师范学院 一种酪氨酸激酶抑制剂azd3759的制备方法
CN111848584A (zh) * 2020-07-10 2020-10-30 江南大学 一种多取代喹唑啉类化合物及其应用
CN113943273A (zh) * 2020-07-17 2022-01-18 上海天慈国际药业有限公司 一种肺癌药物azd3759的制备方法
CN113135901A (zh) * 2021-04-12 2021-07-20 南京雷正医药科技有限公司 氘代的喹唑啉类盐酸盐化合物的晶型及其制备和应用
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
KR20250006237A (ko) 2022-04-28 2025-01-10 아스트라제네카 아베 축합 바이사이클릭 헤테로방향족 화합물 및 암의 치료에서의 이의 용도
WO2023209088A1 (fr) 2022-04-28 2023-11-02 Astrazeneca Ab Composés hétéroaromatiques bicycliques et leur utilisation dans le traitement du cancer
WO2023209090A1 (fr) 2022-04-28 2023-11-02 Astrazeneca Ab Composés hétéroaromatiques bicycliques et leur application dans le traitement du cancer
WO2023209086A1 (fr) 2022-04-28 2023-11-02 Astrazeneca Ab Composés hétéroaromatiques bicycliques pour le traitement du cancer
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
CN115813927A (zh) * 2022-07-06 2023-03-21 江苏晨泰医药科技有限公司 受体酪氨酸激酶抑制剂与联苯环辛二稀木脂素的联合用药及其用途
EP4551226A1 (fr) 2022-07-08 2025-05-14 Astrazeneca AB Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique en combinaison avec des inhibiteurs du récepteur hgf pour le traitement du cancer
JP2026506169A (ja) * 2023-02-21 2026-02-20 プロセッタ バイオサイエンシズ， インク． キナゾリン化合物及び使用
CN118063441B (zh) * 2024-02-03 2025-09-19 四川大学华西医院 一种氨基喹唑啉类化合物的制备及抗肿瘤作用
CN119192146B (zh) * 2024-08-16 2025-08-29 安徽法尔麦斯生物科技有限公司 一种抑制剂化合物及应用和治疗癌症的药物
CN121085897A (zh) * 2025-01-21 2025-12-09 安徽医科大学 一类具有抗炎活性的喹唑啉类化合物或其药学上可接受的盐、药物组合物及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP2003509497A (ja) 1999-09-21 2003-03-11 アストラゼネカ アクチボラグ キナゾリン化合物とそれらを含有する医薬組成物
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
EP1492536B1 (fr) * 2002-03-30 2012-05-09 Boehringer Ingelheim Pharma GmbH & Co.KG 4-(n-phenylamino)-quinazolines / quinolines en tant qu'inhibiteurs de la tyrosine kinase
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
WO2004056875A1 (fr) 2002-12-23 2004-07-08 Wyeth Anticorps anti pd-1 et utilisations
JP2007500177A (ja) 2003-07-29 2007-01-11 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体
CA2541100A1 (fr) 2003-09-16 2005-03-24 Astrazenca Ab Derives de quinazoline
MXPA06003113A (es) 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
CN1882570B (zh) 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
WO2005097134A2 (fr) 2004-03-31 2005-10-20 The Scripps Research Institute Inhibiteurs de proteine kinase a base de quinazoline
EP3611273A1 (fr) 2004-03-31 2020-02-19 The General Hospital Corporation Procédé pour déterminer la réactivité du cancer aux traitements de ciblage de récepteur de facteur de croissance épidermique
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CN101175732B (zh) 2005-05-12 2010-06-16 黄文林 一种喹唑啉衍生物的制备方法及用作制备治疗肿瘤疾病药物的应用
CN101175734B (zh) 2005-05-12 2011-10-12 黄文林 一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
EP1919900A2 (fr) 2005-08-22 2008-05-14 Boehringer Ingelheim International Gmbh Heterocycles bicycliques, produits pharmaceutiques contenant ces composes, leur utilisation et procede pour les preparer
CA2755268C (fr) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Inhibiteurs erbb
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
BRPI0602275A (pt) 2006-03-24 2007-11-27 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e processo para a preparação de um derivado de quinalizona
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN101367793B (zh) 2008-09-26 2013-09-11 中国科学院广州生物医药与健康研究院 一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
WO2010061208A2 (fr) 2008-11-03 2010-06-03 Astrazeneca Ab Traitement therapeutique 555
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
NO2504364T3 (fr) 2009-11-24 2018-01-06
RS61281B1 (sr) 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
CN101857618B (zh) 2010-06-13 2015-11-25 中国海洋大学 作为蛋白酪氨酸激酶抑制剂的一系列喹唑啉糖衍生物，其制备方法和应用
WO2012027328A2 (fr) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
MX362247B (es) * 2013-03-06 2019-01-09 Astrazeneca Ab Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico.

Also Published As

Publication number Publication date
IL240578B (en) 2019-03-31
NI201500123A (es) 2016-02-16
ME03041B (fr) 2018-10-20
RU2656597C2 (ru) 2018-06-06
AU2014224382B2 (en) 2016-11-10
HK1216315A1 (en) 2016-11-04
HUE034568T2 (en) 2018-02-28
KR20150083782A (ko) 2015-07-20
SMT201700542T1 (it) 2018-01-11
CA2901269A1 (fr) 2014-09-12
NZ710850A (en) 2020-09-25
US20160340342A1 (en) 2016-11-24
US9066979B2 (en) 2015-06-30
US20140255428A1 (en) 2014-09-11
CN105209456A (zh) 2015-12-30
IL240578A0 (en) 2015-09-24
SI2964638T1 (sl) 2017-11-30
TWI543977B (zh) 2016-08-01
TW201520206A (zh) 2015-06-01
PH12015501965A1 (en) 2016-01-11
SG11201506487YA (en) 2015-09-29
CN105209456B (zh) 2018-05-08
UA115686C2 (uk) 2017-12-11
BR112015020787A2 (pt) 2017-07-18
US20180016259A1 (en) 2018-01-18
PH12015501965B1 (en) 2021-08-04
UY35369A (es) 2014-08-29
HRP20171689T1 (hr) 2018-02-23
RS56566B1 (sr) 2018-02-28
PT2964638T (pt) 2017-11-14
WO2014135876A1 (fr) 2014-09-12
US20150320751A1 (en) 2015-11-12
EP2964638A1 (fr) 2016-01-13
PL2964638T3 (pl) 2018-01-31
EP2964638B1 (fr) 2017-08-09
CA2901269C (fr) 2022-01-18
KR101645112B1 (ko) 2016-08-02
LT2964638T (lt) 2017-12-27
NO2964638T3 (fr) 2018-01-06
US9375432B2 (en) 2016-06-28
MY186126A (en) 2021-06-24
MX362247B (es) 2019-01-09
EP3342770A1 (fr) 2018-07-04
US9718806B2 (en) 2017-08-01
RU2015139513A (ru) 2017-04-10
AP2015008696A0 (en) 2015-08-31
TN2015000368A1 (en) 2017-01-03
CY1119487T1 (el) 2018-03-07
CR20150450A (es) 2015-12-01
JP5894714B1 (ja) 2016-03-30
PE20152000A1 (es) 2016-01-22
CL2015002361A1 (es) 2016-01-04
AU2014224382A1 (en) 2015-09-03
JP2016511225A (ja) 2016-04-14
AR095039A1 (es) 2015-09-16
DK2964638T3 (en) 2017-10-30
EP3342770B1 (fr) 2022-03-30
ES2642201T3 (es) 2017-11-15
GT201500251A (es) 2017-10-09
ZA201507353B (en) 2017-03-29
BR112015020787B1 (pt) 2022-12-06
MX2015011818A (es) 2016-01-08
DOP2015000189A (es) 2015-08-31

Similar Documents

Publication Publication Date Title
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
EP4104837A3 (fr) Composés hétérocliques comme inhibiteurs de la kinase ret
EA201201161A1 (ru) Пирролопиримидины в качестве ингибиторов cdk4/6
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
PH12015502365A1 (en) Bace1 inhibitors
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
PH12017501668A1 (en) Bace1 inhibitors
MA35010B1 (fr) Inhibiteurs de la peptide déformylase
MX365292B (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
FR3028762B1 (fr) Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine
NZ800047A (en) Benzimidazolone derived inhibitors of bcl6
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA39719B1 (fr) Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak